4basebio AG reports change in Supervisory Board and new appointment to the Executive Management Board

Business news for the stock market

Heidelberg (pta008/02.12.2020/07:30) - 4basebio AG (Frankfurt: 4BSB; ISIN: DE000A2YN801; Prime Standard) announced today that the previous member of the company’s Supervisory Board, Mr Hansjörg Plaggemars, resigned from his office as a member of the company’s Supervisory Board by letter dated 29 November 2020.

Mr Alexander Link, who was elected as a substitute member of the Supervisory Board during the Extraordinary General Meeting of the Company on 3 November 2020, thus automatically takes over the Supervisory Board mandate from Mr Plaggemars. The quorum of the Supervisory Board of the Company is thus ensured.

In addition, the Supervisory Board appointed Hansjörg Plaggemars to the Executive Management Board of 4basebio AG at its meeting yesterday. Mr Plaggemars will become the third member of the Executive Management Board alongside Dr Heikki Lanckriet and David Roth.

For further information, please contact:

4basebio AG

Dr. Heikki Lanckriet, Executive Management Board Member

Phone: +44 1223 873 364

Email: [email protected]

Dr. Robert Mayer, Manager IR

Phone: +49 171 3876540

Email: [email protected]

MC Services AG (Investor Relations and International Media Relations)

Julia Hofmann

Phone: +49 89 210228 0

Email: [email protected]

About 4basebio AG:

4basebio AG, formerly operating under the name of Expedeon AG, is an enabler of exciting advances in medical science and patient care. After divestment of its immunology and proteomics products portfolio on 1 January 2020, the Company changed its name to 4basebio AG reflecting the enhanced focus on technologies and products centered around DNA. The Company is focusing on DNA manufacturing to supply DNA products for therapeutic and other uses requiring large amounts of high-purity DNA, such as the fast-growing market of novel gene therapies and gene vaccines. Besides DNA manufacturing, 4basebio aims at providing research and diagnostic products based on its RNA reverse transcriptase, DNA polymerase and DNA primase enzymes, addressing the research tools and diagnostic products markets.

4basebio AG has offices in Germany, Spain and UK. The Company is listed on the Prime Standard segment of the Frankfurt Stock Exchange (Ticker: 4BSB; ISIN: DE000A2YN801).

More information: www.investors.4basebio.com

# # # This publication is intended for information only and constitutes neither an offer to sell nor an invitation to buy securities. Some statements included in this press release, relating neither to proven financial results nor other historical data, should be viewed as forward-looking, i.e. not definite. Such statements are mainly predictions of future results, trends, plans or goals. These statements should not be considered to be total guarantees since given their very nature they are subject to known and unknown risks and imponderability and can be affected by other factors as a consequence of which the actual results, plans and goals of 4basebio AG may deviate greatly from the established conclusions or implied predictions contained in such statements. 4basebio does not undertake to publicly update or revise these statements in the light of new information or future results or for any other reason. # # #


emitter: 4basebio AG

address: Waldhofer Str. 102, 69123 Heidelberg

country: Germany

contact person: Robert Mayer

phone: +49 171 3876540

e-mail: [email protected]

website: investors.4basebio.com

ISIN(s): DE000A2YN801 (share)

stock exchanges: regulated market in Frankfurt; free market in Stuttgart, free market in Munich, free market in Hamburg, free market in Dusseldorf; open market in Berlin, Tradegate

[ source: http://www.pressetext.com/news/20201202008 ]